![Klaus Binder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Klaus Binder
Amministratore Delegato presso Binder Associates GmbH
Profilo
Klaus Binder is the founder of Binder Associates GmbH.
He is currently the Chairman of Abalos Therapeutics GmbH.
Previously, he served as the Chairman-Supervisory Board of amaxa GmbH, Director of Natrix Separations, Inc., and Principal at Boehringer Ingelheim GmbH and Boehringer Ingelheim Pharma GmbH & Co., KG.
Posizioni attive di Klaus Binder
Società | Posizione | Inizio |
---|---|---|
Binder Associates GmbH | Amministratore Delegato | - |
Abalos Therapeutics GmbH
![]() Abalos Therapeutics GmbH BiotechnologyHealth Technology Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany. | Presidente | 05/02/2020 |
Precedenti posizioni note di Klaus Binder
Società | Posizione | Fine |
---|---|---|
NATRIX Separations, Inc.
![]() NATRIX Separations, Inc. Medical SpecialtiesHealth Technology NATRIX Separations, Inc. manufactures and supplies single use and multi-cycle disposable chromatography products to the life science, food, beverage and water markets. Its technology consists of a polymeric hydrogel formed within a flexible porous support matrix. The firm offers NatriFlo HD-Q membrane absorbers for single-use flow-through polish applications and Natrix HD-C hydrogel membrane devices for bind-elute applications. The company was founded by Alicja Mika, Lisa Crossley, and Ronald F. Childs in 2004 and is headquartered in Burlington, Canada. | Direttore/Membro del Consiglio | 01/09/2017 |
Boehringer Ingelheim Pharma GmbH & Co., KG
![]() Boehringer Ingelheim Pharma GmbH & Co., KG BiotechnologyHealth Technology Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co., KG is a company that operates research-based pharmaceutical companies and serves. Boehringer Ingelheim Pharma GmbH & Co., KG is based in Ingelheim, Germany. The German company was founded in 1885 by Albert Boehringer. The CEO is Hubertus von Baumbach. | Corporate Officer/Principal | - |
Boehringer Ingelheim GmbH
![]() Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Corporate Officer/Principal | - |
amaxa GmbH
![]() amaxa GmbH Miscellaneous Commercial ServicesCommercial Services amaxa GmbH researches gene transfer and gene-based medicines to develop causal therapies for the treatment of severe diseases. It focuses on high-end applications for non-viral delivery of genes and transfer of other charged substrates into cells. The company was founded in 1998 and is headquartered in Cologne, Germany. | Presidente | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 6 |
---|---|
Boehringer Ingelheim GmbH
![]() Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Boehringer Ingelheim GmbH engages in the provision of central management and other services for the group companies on behalf of C.H. Boehringer Sohn AG & Co. KG. The group specializes in the development, production, and distribution of pharmaceutical products. The company was founded in 1885 and is headquartered in Ingelheim am Rhein, Germany. | Health Technology |
amaxa GmbH
![]() amaxa GmbH Miscellaneous Commercial ServicesCommercial Services amaxa GmbH researches gene transfer and gene-based medicines to develop causal therapies for the treatment of severe diseases. It focuses on high-end applications for non-viral delivery of genes and transfer of other charged substrates into cells. The company was founded in 1998 and is headquartered in Cologne, Germany. | Commercial Services |
NATRIX Separations, Inc.
![]() NATRIX Separations, Inc. Medical SpecialtiesHealth Technology NATRIX Separations, Inc. manufactures and supplies single use and multi-cycle disposable chromatography products to the life science, food, beverage and water markets. Its technology consists of a polymeric hydrogel formed within a flexible porous support matrix. The firm offers NatriFlo HD-Q membrane absorbers for single-use flow-through polish applications and Natrix HD-C hydrogel membrane devices for bind-elute applications. The company was founded by Alicja Mika, Lisa Crossley, and Ronald F. Childs in 2004 and is headquartered in Burlington, Canada. | Health Technology |
Boehringer Ingelheim Pharma GmbH & Co., KG
![]() Boehringer Ingelheim Pharma GmbH & Co., KG BiotechnologyHealth Technology Part of C.H. Boehringer Sohn AG & Co. KG, Boehringer Ingelheim Pharma GmbH & Co., KG is a company that operates research-based pharmaceutical companies and serves. Boehringer Ingelheim Pharma GmbH & Co., KG is based in Ingelheim, Germany. The German company was founded in 1885 by Albert Boehringer. The CEO is Hubertus von Baumbach. | Health Technology |
Binder Associates GmbH | |
Abalos Therapeutics GmbH
![]() Abalos Therapeutics GmbH BiotechnologyHealth Technology Abalos Therapeutics GmbH engages in the development of an anti-cancer arenavirus-based drug. It focuses on awakening immune responses against tumors and metastases. The company was founded by Karl Lang and Philipp Lang and is headquartered in Essen, Germany. | Health Technology |
- Borsa valori
- Insiders
- Klaus Binder